Tab Application Banner
  • Users Online: 1385
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2012  |  Volume : 7  |  Issue : 2  |  Page : 83-88

Methotrexate induced pneumonitis

PD Hinduja National Hospital and Medical Research Center, Veer Savarkar Marg, Mahim, Mumbai 400016, India

Correspondence Address:
Vinay Ramachandra Joshi
PD Hinduja National Hospital and Medical Research Center, Veer Savarkar Marg, Mahim, Mumbai 400016
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.1016/j.injr.2012.04.001

Rights and Permissions

Methotrexate induced pneumonitis (MTX-P) is an uncommon, but potentially serious and life-threatening adverse event. The dose, duration of treatment and route of administration of methotrexate bear no relationship to MTX-P. Many risk factors have been studied but no definitive risk factor is identified. Pre-existing pulmonary disease may be associated with increased risk of MTX-P. Several sets of criteria have been proposed for diagnosis of MTX-P but none are validated. Diagnosis is mainly clinical and requires a high degree of suspicion. Treatment is mainly supportive along with discontinuation of methotrexate. Most patients recover. Mortality up to 17% has been reported in literature. Reintroduction of methotrexate after recovering from MTX-P is generally avoided. This article focuses on the epidemiology, clinical presentation, pathology, laboratory features and management of MTX-P.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded444    
    Comments [Add]    
    Cited by others 1    

Recommend this journal